Literature DB >> 20486768

Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material.

Martin Lock1, Susan McGorray, Alberto Auricchio, Eduard Ayuso, E Jeffrey Beecham, Véronique Blouin-Tavel, Fatima Bosch, Mahuya Bose, Barry J Byrne, Tina Caton, John A Chiorini, Abdelwahed Chtarto, K Reed Clark, Thomas Conlon, Christophe Darmon, Monica Doria, Anne Douar, Terence R Flotte, Joyce D Francis, Achille Francois, Mauro Giacca, Michael T Korn, Irina Korytov, Xavier Leon, Barbara Leuchs, Gabriele Lux, Catherine Melas, Hiroaki Mizukami, Philippe Moullier, Marcus Müller, Keiya Ozawa, Tina Philipsberg, Karine Poulard, Christina Raupp, Christel Rivière, Sigrid D Roosendaal, R Jude Samulski, Steven M Soltys, Richard Surosky, Liliane Tenenbaum, Darby L Thomas, Bart van Montfort, Gabor Veres, J Fraser Wright, Yili Xu, Olga Zelenaia, Lorena Zentilin, Richard O Snyder.   

Abstract

A recombinant adeno-associated virus serotype 2 Reference Standard Material (rAAV2 RSM) has been produced and characterized with the purpose of providing a reference standard for particle titer, vector genome titer, and infectious titer for AAV2 gene transfer vectors. Production and purification of the reference material were carried out by helper virus-free transient transfection and chromatographic purification. The purified bulk material was vialed, confirmed negative for microbial contamination, and then distributed for characterization along with standard assay protocols and assay reagents to 16 laboratories worldwide. Using statistical transformation and modeling of the raw data, mean titers and confidence intervals were determined for capsid particles ({X}, 9.18 x 10¹¹ particles/ml; 95% confidence interval [CI], 7.89 x 10¹¹ to 1.05 x 10¹² particles/ml), vector genomes ({X}, 3.28 x 10¹⁰ vector genomes/ml; 95% CI, 2.70 x 10¹⁰ to 4.75 x 10¹⁰ vector genomes/ml), transducing units ({X}, 5.09 x 10⁸ transducing units/ml; 95% CI, 2.00 x 10⁸ to 9.60 x 10⁸ transducing units/ml), and infectious units ({X}, 4.37 x 10⁹ TCID₅₀ IU/ml; 95% CI, 2.06 x 10⁹ to 9.26 x 10⁹ TCID₅₀ IU/ml). Further analysis confirmed the identity of the reference material as AAV2 and the purity relative to nonvector proteins as greater than 94%. One obvious trend in the quantitative data was the degree of variation between institutions for each assay despite the relatively tight correlation of assay results within an institution. This relatively poor degree of interlaboratory precision and accuracy was apparent even though attempts were made to standardize the assays by providing detailed protocols and common reagents. This is the first time that such variation between laboratories has been thoroughly documented and the findings emphasize the need in the field for universal reference standards. The rAAV2 RSM has been deposited with the American Type Culture Collection and is available to the scientific community to calibrate laboratory-specific internal titer standards. Anticipated uses of the rAAV2 RSM are discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20486768      PMCID: PMC2957240          DOI: 10.1089/hum.2009.223

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  20 in total

1.  Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield.

Authors:  S Zolotukhin; B J Byrne; E Mason; I Zolotukhin; M Potter; K Chesnut; C Summerford; R J Samulski; N Muzyczka
Journal:  Gene Ther       Date:  1999-06       Impact factor: 5.250

2.  Proteolytic mapping of the adeno-associated virus capsid.

Authors:  Kim Van Vliet; Veronique Blouin; Mavis Agbandje-McKenna; Richard O Snyder
Journal:  Mol Ther       Date:  2006-09-27       Impact factor: 11.454

3.  Novel tools for production and purification of recombinant adenoassociated virus vectors.

Authors:  D Grimm; A Kern; K Rittner; J A Kleinschmidt
Journal:  Hum Gene Ther       Date:  1998-12-10       Impact factor: 5.695

4.  Factors influencing recombinant adeno-associated virus production.

Authors:  A Salvetti; S Orève; G Chadeuf; D Favre; Y Cherel; P Champion-Arnaud; J David-Ameline; P Moullier
Journal:  Hum Gene Ther       Date:  1998-03-20       Impact factor: 5.695

Review 5.  Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector.

Authors:  J Fraser Wright; Guang Qu; Chunlin Tang; Jurg M Sommer
Journal:  Curr Opin Drug Discov Devel       Date:  2003-03

Review 6.  Treatment of human disease by adeno-associated viral gene transfer.

Authors:  Kenneth H Warrington; Roland W Herzog
Journal:  Hum Genet       Date:  2006-04-13       Impact factor: 4.132

7.  Quantification of adeno-associated virus particles and empty capsids by optical density measurement.

Authors:  Jürg M Sommer; Peter H Smith; Sumathy Parthasarathy; Jesse Isaacs; Sharmila Vijay; Jane Kieran; Sharon K Powell; Alan McClelland; J Fraser Wright
Journal:  Mol Ther       Date:  2003-01       Impact factor: 11.454

8.  Infectious titer assay for adeno-associated virus vectors with sensitivity sufficient to detect single infectious events.

Authors:  Zhu Zen; Yero Espinoza; Thieu Bleu; Jürg M Sommer; J Fraser Wright
Journal:  Hum Gene Ther       Date:  2004-07       Impact factor: 5.695

9.  Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system.

Authors:  Corinna Burger; Oleg S Gorbatyuk; Margaret J Velardo; Carmen S Peden; Philip Williams; Sergei Zolotukhin; Paul J Reier; Ronald J Mandel; Nicholas Muzyczka
Journal:  Mol Ther       Date:  2004-08       Impact factor: 11.454

10.  Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.

Authors:  Richard B Moss; David Rodman; L Terry Spencer; Moira L Aitken; Pamela L Zeitlin; David Waltz; Carlos Milla; Alan S Brody; John P Clancy; Bonnie Ramsey; Nicole Hamblett; Alison E Heald
Journal:  Chest       Date:  2004-02       Impact factor: 9.410

View more
  45 in total

1.  LRH-1-dependent glucose sensing determines intermediary metabolism in liver.

Authors:  Maaike H Oosterveer; Chikage Mataki; Hiroyasu Yamamoto; Taoufiq Harach; Norman Moullan; Theo H van Dijk; Eduard Ayuso; Fatima Bosch; Catherine Postic; Albert K Groen; Johan Auwerx; Kristina Schoonjans
Journal:  J Clin Invest       Date:  2012-07-09       Impact factor: 14.808

Review 2.  Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Nat Rev Genet       Date:  2011-05       Impact factor: 53.242

3.  Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR.

Authors:  Martin Lock; Mauricio R Alvira; Shu-Jen Chen; James M Wilson
Journal:  Hum Gene Ther Methods       Date:  2014-02-14       Impact factor: 2.396

4.  Gene therapy finds its niche.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2011-02       Impact factor: 54.908

5.  Reference Standards for Gene and Cell Therapy Products.

Authors:  Boro Dropulić
Journal:  Mol Ther       Date:  2017-05-11       Impact factor: 11.454

6.  Quantification of Adeno-Associated Virus with Safe Nucleic Acid Dyes.

Authors:  Jian Xu; Steven H DeVries; Yongling Zhu
Journal:  Hum Gene Ther       Date:  2020-07-14       Impact factor: 5.695

7.  Analysis of particle content of recombinant adeno-associated virus serotype 8 vectors by ion-exchange chromatography.

Authors:  Martin Lock; Mauricio R Alvira; James M Wilson
Journal:  Hum Gene Ther Methods       Date:  2012-02       Impact factor: 2.396

8.  Systemic errors in quantitative polymerase chain reaction titration of self-complementary adeno-associated viral vectors and improved alternative methods.

Authors:  Paolo Fagone; J Fraser Wright; Amit C Nathwani; Arthur W Nienhuis; Andrew M Davidoff; John T Gray
Journal:  Hum Gene Ther Methods       Date:  2012-02       Impact factor: 2.396

9.  AAV-ID: A Rapid and Robust Assay for Batch-to-Batch Consistency Evaluation of AAV Preparations.

Authors:  Simon Pacouret; Mohammed Bouzelha; Rajani Shelke; Eva Andres-Mateos; Ru Xiao; Anna Maurer; Mathieu Mevel; Heikki Turunen; Trisha Barungi; Magalie Penaud-Budloo; Frédéric Broucque; Véronique Blouin; Philippe Moullier; Eduard Ayuso; Luk H Vandenberghe
Journal:  Mol Ther       Date:  2017-04-17       Impact factor: 11.454

10.  Homologous Recombination-Based Genome Editing by Clade F AAVs Is Inefficient in the Absence of a Targeted DNA Break.

Authors:  Geoffrey L Rogers; Hsu-Yu Chen; Heidy Morales; Paula M Cannon
Journal:  Mol Ther       Date:  2019-09-09       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.